Syndax Pharmaceuticals Inc (SNDX)
21.76
-0.21
(-0.96%)
USD |
NASDAQ |
May 10, 16:00
21.76
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Total Assets (Quarterly): 543.03M for March 31, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 543.03M |
| December 31, 2023 | 612.88M |
| September 30, 2023 | 399.22M |
| June 30, 2023 | 431.34M |
| March 31, 2023 | 459.83M |
| December 31, 2022 | 497.24M |
| September 30, 2022 | 359.69M |
| June 30, 2022 | 406.44M |
| March 31, 2022 | 422.22M |
| December 31, 2021 | 449.66M |
| September 30, 2021 | 239.50M |
| June 30, 2021 | 263.06M |
| March 31, 2021 | 279.67M |
| December 31, 2020 | 300.61M |
| September 30, 2020 | 179.31M |
| June 30, 2020 | 192.63M |
| March 31, 2020 | 105.16M |
| December 31, 2019 | 63.52M |
| September 30, 2019 | 76.38M |
| June 30, 2019 | 87.39M |
| Date | Value |
|---|---|
| March 31, 2019 | 99.39M |
| December 31, 2018 | 83.94M |
| September 30, 2018 | 96.47M |
| June 30, 2018 | 105.37M |
| March 31, 2018 | 119.96M |
| December 31, 2017 | 137.19M |
| September 30, 2017 | 124.49M |
| June 30, 2017 | 134.67M |
| March 31, 2017 | 97.67M |
| December 31, 2016 | 109.01M |
| September 30, 2016 | 117.73M |
| June 30, 2016 | 127.86M |
| March 31, 2016 | 136.26M |
| December 31, 2015 | 89.90M |
| September 30, 2015 | 102.84M |
| December 31, 2014 | 12.82M |
| September 30, 2014 | 12.33M |
| June 30, 2014 | 9.66M |
| March 31, 2014 | 13.08M |
| December 31, 2013 | 17.06M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
63.52M
Minimum
Dec 2019
612.88M
Maximum
Dec 2023
318.44M
Average
330.15M
Median
Total Assets (Quarterly) Benchmarks
| Geron Corp | 482.07M |
| Verastem Inc | 149.72M |
| Karyopharm Therapeutics Inc | 240.44M |
| Crinetics Pharmaceuticals Inc | 635.35M |
| Arvinas Inc | 1.213B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 51.14M |
| Shareholders Equity (Quarterly) | 491.89M |